Letter of comment on "Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial" (Am Heart J 2006;152:887.e9-14).
Vydt
Tom
T
Agostoni
Pierfrancesco
P
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D003326:Coronary Circulation / Q000187:drug effects*; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007269:Injections, Intra-Arterial; D009203:Myocardial Infarction / Q000628:therapy*; D009599:Nitroprusside / Q000008:administration & dosage*; D011300:Preoperative Care / Q000379:methods; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*
D014665:Vasodilator Agents; D009599:Nitroprusside